Disc Medicine 的 DISC-3405 获得 FDA 孤儿药称号，该药用于治疗真性红细胞增多症（一种罕见的血液疾病）。 Disc Medicine receives FDA orphan drug designation for DISC-3405, a treatment for polycythemia vera, a rare blood disorder.
Disc Medicine 的 DISC-3405 已获得孤儿药资格，该药用于治疗真性红细胞增多症（一种罕见的血液疾病）。 Disc Medicine has received Orphan Drug Designation for DISC-3405, its treatment for polycythemia vera, a rare blood disorder. 这一称号提供了诸如药物开发援助、临床费用税收抵免、FDA 某些费用豁免以及七年批准后营销独占权等福利。 This designation provides benefits like assistance in drug development, tax credits for clinical costs, exemptions from certain FDA fees, and seven years of post-approval marketing exclusivity. 该公司计划于 2024 年上半年分享正在进行的 DISC-3405 第一阶段试验的初始数据。 The company plans to share initial data from an ongoing Phase 1 trial of DISC-3405 in the first half of 2024.